278 related articles for article (PubMed ID: 9361959)
1. Safety aspects of pegylated liposomal doxorubicin in patients with cancer.
Alberts DS; Garcia DJ
Drugs; 1997; 54 Suppl 4():30-5. PubMed ID: 9361959
[TBL] [Abstract][Full Text] [Related]
2. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
3. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
Coukell AJ; Spencer CM
Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin in ovarian cancer.
Green AE; Rose PG
Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964
[TBL] [Abstract][Full Text] [Related]
6. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers.
Muggia FM
Drugs; 1997; 54 Suppl 4():22-9. PubMed ID: 9361958
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil).
Skubitz KM; Skubitz AP
Anticancer Drugs; 1998 Jan; 9(1):45-50. PubMed ID: 9491791
[TBL] [Abstract][Full Text] [Related]
10. From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
Cattel L; Ceruti M; Dosio F
Tumori; 2003; 89(3):237-49. PubMed ID: 12908776
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.
Gordon AN; Granai CO; Rose PG; Hainsworth J; Lopez A; Weissman C; Rosales R; Sharpington T
J Clin Oncol; 2000 Sep; 18(17):3093-100. PubMed ID: 10963637
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
Northfelt DW; Dezube BJ; Thommes JA; Levine R; Von Roenn JH; Dosik GM; Rios A; Krown SE; DuMond C; Mamelok RD
J Clin Oncol; 1997 Feb; 15(2):653-9. PubMed ID: 9053490
[TBL] [Abstract][Full Text] [Related]
13. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.
Sharpe M; Easthope SE; Keating GM; Lamb HM
Drugs; 2002; 62(14):2089-126. PubMed ID: 12269857
[TBL] [Abstract][Full Text] [Related]
14. Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing.
Rose PG; Purpura D; Petersen L
Anticancer Drugs; 2019 Jul; 30(6):636-639. PubMed ID: 30973518
[TBL] [Abstract][Full Text] [Related]
15. A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer.
Chao TC; Wang WS; Yen CC; Chiou TJ; Liu JH; Chen PM
Cancer Invest; 2003; 21(6):837-47. PubMed ID: 14735687
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
18. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
20. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
